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Abstract 
The 2014-2015 outbreak of Ebola virus disease (EVD) is the largest epidemic to date in terms of 
number of cases, of death and affected areas. In October 2015, no antiviral agents had proven an 
antiviral efficacy in patients. However in September 2014 WHO inventoried and regularly updated 
since then a list of potential drug candidates with demonstrated antiviral efficacy in vitro or in animal 
models. This includes agents belonging to various therapeutic classes, namely direct antiviral agents 
(favipiravir and BCX4430), combination of antibodies (ZMapp), type I interferons, RNA interference-
based drugs (TKM-Ebola and AVI-7537) and anticoagulant drug (rNAPc2).  
Here, we review the pharmacokinetic and pharmacodynamic information that are presently available 
on these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in 
human clinical trials or animal models for pharmacodynamics.  Future studies evaluating these drugs 
in clinical trials will be critical to confirm their efficacy in humans, propose appropriate doses and 
evaluate the possibility of treatment combinations.  
 
Keypoints 
In response to the 2014-2015 outbreak in West Africa, WHO prioritized a list of drug candidates 
developed or repurposed for Ebola virus infection treatment. 
Here we reported available information on pharmacokinetics and pharmacodynamics of the drugs 
which can be considered for clinical development or have already been tested in clinical trials in July 
2015, according to WHO. 
As most information was gathered from healthy volunteer and non-human primate studies, assessment 
of these drugs in Ebola virus infected patients will require further investigation.  
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1. Introduction 
1.1. Epidemiology 
Ebola virus (EBOV) was first discovered in 1976 when an outbreak of Ebola hemorrhagic fever 
occurred in central Africa and caused 280 deaths out of 318 confirmed cases [1]. Since then, 24 
outbreaks have occurred in several African countries. The 2014-2015 outbreak initiated in Guinea  
before spreading to Sierra Leone, Liberia and other surrounding countries is the most severe and 
deadly outbreak so far with 28331 reported cases and 11310 reported deaths up to September 20
th
2015 
[2], corresponding to an overall fatality rate of 40%. Depending on viral strain and available medical 
care, larger fatality rates up to 90% in some settings have been previously reported [3].  
1.2. Ebola virus 
Genus Ebolavirus belongs the Filoviridae family, order Mononegavirales. It includes four EBOV 
species highly pathogenic in humans: Zaire ebolavirus (responsible for the majority of cases reported 
until now), Sudan ebolavirus, Bundibugyo ebolavirus and Taï Forest ebolavirus (formerly Cote 
d’Ivoire ebolavirus) [4,5]. EBOV is a lipid enveloped, heavily glycosylated, non-segmented negative 
strand RNA virus (Figure 1) [6,7]. Phylogenetic analysis indicates that the agent causing the recent 
outbreak in Western Africa, EBOV-Guinea, with isolated reference strains EBOV-Makona and 
EBOV-Gueckedou, belongs to an evolutionary lineage within the species Zaire ebolavirus[8].  
1.3. Natural history of the disease 
EBOV is transmitted between humans by mucosae contact with infected fluid [9]. Previous studies 
based on seroprevalence analysis in various African populations [10] have shown that filovirus 
infections can commonly be associated with asymptomatic or mild infections and that EBOV genome 
could be detected in the blood of asymptomatic seroconverters exposed to documented EBOV 
symptomatic patients [11].  After an incubation period of 6-12 days, symptomatic patients enter an 
acute phase of infection during which they become highly contagious [6].First symptom onset 
associates fever, asthenia, myalgia and progressive gastrointestinal syndrome, including diarrhea and 
vomiting. This can lead to intravascular volume depletion, electrolyte perturbations, 
hypoperfusion,multi-organ failure including severe renal impairment and finally shock [6,12]. Lately, 
disseminated intravascular coagulation and blood leakage, consequence of massive cytokines release 
and viral replication in endothelial cells, may lead to hemorrhage syndrome, mostly represented by 
gastro-intestinal bleeding. However, in the current outbreak, only less than 20% of patients present 
bleeding [13]. In the case series of Sierra Leone, average time from reported onset of symptoms to 
death was 10 days, and survivingpatients were discharged after a mean illness duration of 21 days 
[12].  
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1.4. Medical care 
1.4.1.   Supportive care 
In the absence of an approved specific treatment, current medical care primarily relies on intensive 
supportive care [13], in particular intravenous fluids and electrolytes solution, oral rehydration to 
maintain intravascular volume. Sepsis management and blood transfusion can also be considered. 
Treatment of other concomitant disease such as malaria is recommended along with empiric 
antibiotics for enteric pathogens especially at the gastrointestinal phase of the illness[13,14].  
1.4.2.   Convalescent plasma 
The use of convalescent plasma was among the first therapeutic approaches. These plasmas, collected 
in patient who recovered from EBOV infection, are expected to contain polyclonal immunoglobulins 
targeting EBOV proteins [15]. However, the kinetics of appearance of immunoglobulins to EBOV, 
and more importantly that of sero-neutralizing antibodies are poorly characterized. They seem to be 
slower than in classical acute viral infections, probably because of the deepfunctional 
immunodeficiency observed during the disease. In fact albeit clinical trials have attempted to assess 
the efficacy of convalescent plasma, no conclusive evidence has been reported yet [15].  
1.4.3.   Current approaches for specific treatment 
In order to accelerate and rationalize the evaluation of these putative agents, WHO issued in 2014 and 
has frequently updated since then a document for Categorization and prioritization of drugs for 
consideration for testing or use in patients infected with Ebola[16]. Here we review the 
pharmacokinetic and pharmacodynamic properties reported for the drugs categorized in class A and B 
in the 3 July 2015 document, which are already or can be considered for clinical trial. These drugs are 
antivirals (favipiravir, BCX4430), immunotherapy based on monoclonal antibodies (ZMapp), or on 
immunomodulation (type-I interferons (IFN)) and antisense therapy such as small interfering RNAs 
(TKM-Ebola) or oligonucleotides (AVI-7537). Other intervention based on drugs approved for other 
diseases have been proposed, but will not be developed here as there is a lack of information on their 
efficacy in EBOV disease.  
In the following session, we report, for each drug candidate, chemical structure or composition, 
mechanism of action (Table 1 and Figure 2), pharmacokinetic characteristics in human or alternatively 
in animals (Table 2), available data on safety, in vitro EC50 assessment (Table 3), efficacy in non-
human primates (NHP) studies (Table 4 and Figure 3) if available or alternatively in rodent. Case 
reports and clinical trials are described to support efficacy in EBOV infected patients. 
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2. Drug candidates 
2.1. Favipiravir 
Favipiravir (T-705) is a broad spectrum antiviral developed by Toyama Chemical Co Ltd. It has been 
approved in Japan and is now in phase III of clinical development in USA for the treatment of 
complicated or resistant flu [17]. Favipiravir is a purine nucleic acid analogue which is ribosylated and 
phosphorylated intracellularly into its active form, T-705RTP. This active metabolite then interferes 
with viral replication, probably by inhibiting the RNA-dependent RNA polymerase [18]. It was also 
found to increase the mutation rate of virus as observed with the influenza virus [19].  
2.1.1.   Pharmacokinetics& Safety 
The pharmacokinetics of favipiravir was firstly characterized in Japanese healthy volunteers in several 
dose escalating trials with doses ranging from 30 to 2400 mg for single administration and from 800 to 
1200 mg daily for repeated administration. After a single oral dose, favipiravir concentration increases 
to Cmax within 2 hours and then decreases rapidly with an elimination rate corresponding to a short 
half-life of 2-5.5h [Toyama in house documentation]. Both Tmax and half-life increase after multiple 
doses. Favipiravir is eliminated via metabolism, mainly by aldehyde oxidase, leading to the inactive 
metabolite T705M1, and marginally by xanthine oxidase. Most metabolites are excreted under 
hydroxylated forms via kidney. The fraction of metabolites excreted in the urine increases over time to 
reach 80-100% after 7 days. Favipiravir exhibits a dose- and time-dependent pharmacokinetics which 
is possibly due to saturation and/or auto-inhibition of the main enzymatic pathway, as favipiravir was 
shown to inhibit aldehyde oxidase in vitro [20]. During the clinical development of favipiravir in 
USA, a lower plasma concentration of approximately 50% has been observed in American patients as 
compared to Japanese patients.  
The most frequent adverse events of favipiravir reported during the development for influenza 
treatment include mild to moderate diarrhea, asymptomatic increase of blood uric acid and 
transaminases and decrease of neutrophil count [20].  
2.1.2.   Efficacy 
Favipiravir was shown to have a high activity against EBOV in vitro. It effectively blocks the 
production of infectious virus with an EC50 of 10 µg/mL in an in vitro experiment using Vero E6 cells 
and wild-type Zaire EBOV Mayinga 1976 strain [21]. A higher EC50 value of about 31 – 63 µg/mL 
was reported in another study, using Vero C1008 cells and EBOV E718/ EBOV Kikwit strains [22]. 
Preclinical data in murine models also demonstrated a strong efficacy of favipiravir against EBOV. In 
one study, A129 IFNα/β receptor−/− knockout mice were challenged by aerosol inoculation of 1000 
focus-forming units (FFU) of wild-type EBOV E718 and then left untreated (N=12) or treated with 
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150 mg/kg BID one hour post-challenge (N=6)[22]. All mice starting treatmentat day 6 survived 
whereas all untreated mice died within 8 days post-challenge. In another study, C57BL/6 IFNα/β 
receptor
−/−
 knockout mice were challenged by intranasal inoculation of 1000 FFU of Zaire 1976 
EBOV and then left untreated (N=10) or treated with 150 mg/kg BID starting from day 6 (N=5) or day 
8 (N=5) post-challenge. All mice receiving treatment at day 6 survived, while untreated mice and 
those receiving treatment at day 8 died within 10 days after infection [21]. The strong antiviral effect 
of favipiravir, with an average effectiveness in blocking viral production of 99.6% at steady-state was 
confirmed in a pharmacokinetic-viral kinetic model developed to characterize the data of the second 
study [23].  However the analysis revealed that time was needed to achieve this steady state, with an 
anti-viral effectiveness of only 49.9% and 94.6% at day 1 and 2, suggesting that favipiravir, in order to 
be fully effective, needs to be administered early. Studies in NHP models are ongoing but data are not 
yet available. 
In fall 2014, at the peak of the epidemics, favipiravir was the only drug meeting the three following 
criteria: strong antiviral effect in animal model, good safety profile and large stocks readily available. 
This prompted the decision to evaluate favipiravir in a non-comparative proof-of-concept trial, in 
which all patients received favipiravir along with standardized care (JIKI trial) [24]. Using a 
modelling approach based on the pharmacokinetic data obtained in Japanese and preclinical results, a 
ten-day treatment with a loading dose of 6000 mg on day 1 and a maintenance dose of 2400 mg/day 
was used for adults [25]. These doses are larger than what is approved in Japan for complicated 
influenza (3200 mg on day 1, followed by 1200 mg for 4 days [20]). For children, doses were 
calculated related to body weight [26].  Between December 2014 and April 2015, 126 patients were 
included, with a mortality rate of 52.6% (excluding patients receiving also convalescent plasma, 95% 
confidence interval [43.1%-61.9%]), compared to 55% in the pretrial period [24]. The baseline viral 
load was a critical predictor of survival with a mortality rate of 20% (95% confidence interval [11.6%-
32.4%]) in patients with less than 7.7 log10 copies/mL compared to 91% (95% confidence interval 
[78.8%-96.4%]) in adults with more than 7.7 log10 copies/mL. In patients with less than 7.7 log10 
copies/mL, the pretrial mortality was larger and equal to 30.5 %, suggesting that an effect of 
favipiravir merits further study in this population. Although the absence of comparator group and the 
reduced number of included patients did not allow for a formal safety assessment, no signal of toxicity 
was reported in the JIKI trial [24].  
2.2. BCX4430 
BCX4430 is a broad spectrum antiviral developed by BioCryst Pharmaceuticals, originally intended to 
target hepatitis C virus, but subsequently developed for treatment of filovirus infections such as EBOV 
[27]. BCX4430 isan adenosine analogue, which is metabolized into triphosphate active form, 
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BCX4430-TP. This active metabolite reduces the production of viral RNA by inhibiting the RNA 
polymerase activity via inducing premature termination of RNA chain synthesis [27]. The drug 
nucleotide has high selectivity for viral RNA polymerase. No evidence was found for the 
incorporation of BCX4430 nucleotide into human DNA and RNA [27].  
2.2.1.   Pharmacokinetics& Safety 
The pharmacokinetics of BCX4430 has been only evaluated in animal models, with dosesranging from 
2 to 50 mg/kg. In rodents and cynomolgus macaques, BCX4430 concentration decreases rapidly in the 
plasma with a half-life of 5-10 min [27]. However, the half-life of its principal active metabolite, 
BCX4430-TP, in the liver in rats was substantially longer (6.2 h). High bioavailability and rapid 
absorption via intramuscular route was observed in animal models [27]. In vitro experiments showed 
that BCX4430 exhibited no mutagenicity, produced no detectable chromosomal aberrations in human 
lymphocyte. A phase I study to evaluate the safety, tolerability and pharmacokinetics of BCX4430 is 
ongoing [16]. 
2.2.2. Efficacy 
BCX4430 exhibited a strong in vitro antiviral effect against EBOV with an EC50 of 3.13 µg/mL using 
HeLa cells and EBOV Kikwit strain [27]. The efficacy of BCX4430 against EBOV infection has been 
evaluated in two different NHP models [28–30]. In one study, infected cynomolgus macaques were 
given various doses (from 3.4 to 16 mg/kg BID) 48 hours post-challenge. The results of this study 
showed that BCX4430 significantly prolonged the survival time but did not improve survival rate even 
at the highest dose tested [28]. In another study, infected rhesus macaque monkeys were given high 
intramuscular doses of BCX4430 (16 mg/kg BID or 25 mg/kg BID) 30-120 minutes after virus 
challenge for 14 days[29,30]. At the end of the follow-up period all of six NHP receiving 25 mg/kg 
survived compared to four of six in the group receiving 16 mg/kg and none in the control group (N=3, 
all dead within 9 days). The mean peak viral load (at day 8 in all animals) was 3 log10 copies/mL lower 
in treated NHP compared to untreated NHP (6 vs 9 log10copies/mL, respectively) [29,30]. 
2.3. ZMapp 
ZMapp, developed by Mapp Biopharmaceutical, is a combination of three humanized monoclonal 
antibodies (c13C6, c2G4 and c4G7 in equal proportion) targeting the EBOV glycoprotein [31]. 
ZMapp components are produced by bioengineering in Nicotianabenthamiana, a plant able to express 
pharmaceutical proteins. These antibodies were demonstrated to have large neutralizing activity in 
vitro [31], suggesting ability to link with strong affinity to viral particles, inhibiting their fusion with 
the target cells and enhancing their clearance. Besides, monoclonal antibodies were also thought to 
accelerate the elimination of infected cells expressing viral glycoprotein, through antibody-dependent 
cellular cytotoxicity mechanism or complement [32,33]. 
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Another similar cocktail of three monoclonal antibodies addressing the same binding domain sequence 
as ZMapp, known as MIL-77, is produced by MabWorksusing mammalian Chinese Hamster Ovary 
(CHO) cells to obtain larger yield. Since no proof of equivalence of MIL-77 and Zmapp has been 
provided, WHO recommended to complete ZMapp therapeutic evaluation before considering MIL-77 
[16]. 
2.3.1.   Pharmacokinetics& Safety 
A phase I clinical trial to assess the pharmacokinetics and safety of ZMapp is ongoing in healthy 
volunteers with a unique dose level of 50 mg/kg and results are planned to be released in 2016 [34]. 
Preliminary information on drug’s safety can be obtained from seven infected repatriated patients 
receiving the drug as compassionate therapy. The common side effects reported during 
immunoglobulin infusion were fever, hypotension, tachycardia, rash, polypnea[35], which were 
handled using preventive antihistamine treatment and acetaminophen co-medication. One patient 
experienced generalized seizures, which disappeared after a temporary interruption of treatment.  
2.3.2.   Efficacy 
The efficacy of monoclonal antibodies cocktails, such as MB003 and ZMab,in preventing and treating 
EBOV disease in rodent and NHP has been proved in several studies [36–39], with survival rates of 
50-100% and 43% in rhesus macaques treated with monoclonal antibodies cocktails started at 1 day 
and 5 days after the challenge, respectively[36–38].  
ZMapp combination was obtained by selecting the most efficient antibodies in the MB003 and 
ZMabcocktails[31]. The in vitro EC50 of the three monoclonal antibodies in ZMapp were reported 
between 0.1 and 1 µg/mL using Ebola-Guinea strain in veroE6 cells culture. ZMapp was then 
evaluated in a NHP study where 21 rhesus macaques infected with 628 pfu of Kikwik Ebola virus by 
IM route were left untreated (N=3) or treated with three doses of 50 mg/kg given at three-day interval. 
The treatment was initiated at 3, 4 or 5 days post-challenge (N=6 in each group). All the treated 
animals survived whereas all in the control group died within 8 days after infection. In monkeys 
whose treatment started on day 5 after the challenge, EBOV disease symptoms were reversed by day 7 
and viral load reached the limit of quantitation by day 9 after treatment initiation.   
ZMapp clinical use was restricted due to its limited supply. European Medicines Agency reported that 
five of seven patients who received the drug as a compassionate use at day 6 to 16 after the onset of 
symptom, in combination with intensive supportive care, survived [35]. Yet no imputability can be 
assessed from these single case observations, receiving different dosing and sometime other 
investigational treatments. An adaptive randomized clinical trial is ongoing in West Africa, promoted 
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by NIAID [40] to evaluate the efficacy of ZMapp with other potential candidate treatments as 
comparators, with a fixed dose of 50 mg/kg administered every 3 days. 
2.4. Interferons 
Interferons α and β belong to the class of type-I IFN, a family of cytokines with antiviral, 
antiproliferative andimmunoregulatory properties [41,42]. These cytokines are the major effectors of 
the innate immune response to viral infection, through host cell genes regulation. They hamper 
intracellular viral replication by several mechanisms, including viral mRNA degradation, inhibition of 
viral transcription and translation and interference with the release of viral particles. Besides, they 
enhance infected cells clearance by activating apoptosis mechanism and recruiting cytotoxic cells [43]. 
As EBOV infection is associated with a strong alteration of host immune response, started by the 
downregulation of type-I IFN [44,45] and massive lymphocyte apoptosis [46], IFN supplementation 
may help control the infection and the associated unregulated inflammatory syndrome. Several 
recombinant IFNs with chemical structures close to the natural type I IFNs have been commercialized 
(IFNα-2a, IFNα-2b, IFNβ-1a, IFNβ-1b). 
2.4.1.   Pharmacokinetics& Safety 
Usual dose per injection range is 3 to 36 MIU three times a week for INFα and about 30-44 µg weekly 
for IFNβ, respectively, depending on the indication and administration route. The recombinant type-I 
IFNs are poorly absorbed from the gastrointestinal tract and therefore have to be given parentally 
[47,48]. Following an IV bolus administration, IFN concentration decreases rapidly with a terminal 
half-life of 4-16h for IFNα and 1-2h for IFNβ [47]. By subcutaneous route, IFN has a good 
bioavailability (>80%) and is rapidly absorbed, with peak serum concentrations observed after 1-8 
hours and 3-15 hours for IFNα and IFNβ, respectively [47]. The terminal half-life of IFNβ is 
prolonged in a subcutaneous administration [49].  
The type-I IFNs share a similar safety profile. The most frequently encountered side effects include 
influenza-like symptoms (myalgia, asthenia, fevers, fatigue and headache), neuropsychiatric 
consequences (depression, irritability, memory impairment), myelosuppression (neutropenia and 
thrombocytopenia), dermatological troubles, and the development or exacerbation of autoimmune 
disease, in particular thyroiditis [41,50].  These side effects were reported for long duration treatment, 
and may have lesser impact in short treatments for acute infection. 
2.4.2.   Efficacy 
The antiviral activity of type-I IFN has been proved in vitro in VeroE6 cells, using an engineered 
EBOV (Zaire 76) expressing green fluorescent protein with an EC50 of <0.4 ng/mL for IFNβ and 2 
ng/mL for IFNα [51]. 
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The efficacy of IFNs monotherapy in treating EBOV infection has been evaluated in two NHP studies. 
The results showed that IFN given in monotherapy as post-exposure therapy had no effect on survival 
rates but appeared to prolong the survival time from 6 days in control group (N=2) to 7.5 days in 
cynomolgus monkeys receiving IFNα-2b (N=4) and from 8.3 days in control group (N=26, experiment 
and historical controls) to 13.8 days in monkeys treated with IFNβ (N=5) [52,53]. Peak of viral load 
appeared later, at day 7 post-challenge, in monkeys receiving IFNα-2b (N=4) [52] in comparison with 
non-treated monkeys (peak at day 5 post-challenge, N=2). In a separate study including two species of 
NHP infected by 1000 pfu IM of EBOV Kikwit, administration of IFNα in combination with ZMab at 
day 3 or 4 after the challenge improved the survival rates up to 75% in cynomolgus macaques (N=4) 
and 100% in rhesus macaques (N=4), compared to a survival rate of 50% in ZMab monotherapy 
(N=4) [39,54].   
WHO mentioned an ongoing clinical trial of IFN in Guinea (not yet registered on clinicaltrial.gov at 
the end of September 2015) including patient with early onset of symptoms [16].  
2.5. TKM-Ebola 
TKM-Ebola, developed by Arbutus biopharma (formerly known as Tekmira), belongs to a new 
therapeutic class based on RNA interference technology. This drug is composed of two small 
interfering RNA, siLpol-2 and siVP35-2, whose sequences are complementary to those of EBOV viral 
polymerase and VP35 genes, respectively. As siRNA are very unstable, they are encapsulated and 
protected in lipid nanoparticles coated with polyethylene glycol molecules [35,55]. The two siRNA in 
TKM-Ebola silence the corresponding viral genes by inhibiting mRNA translation and enhancing host 
cell mediated viral mRNA destruction [56]. 
The initial formulation of TKM-Ebola, TKM 100-802 siEbola-2, was 100% sequence complementary 
to the corresponding genes of the EBOV Kikwit strain. However, these siRNA have several 
mismatches when compared to the gene sequences of the EBOV Guinea (Makona) strain. To address 
the potential loss of efficacy, Tekmira developed a new formulation TKM 100-802 siEbola-3 
specifically targeting the Guinea strain[55], the major strain responsible of the outbreak in West 
Africa.  
2.5.1.   Pharmacokinetics& Safety 
The pharmacokinetics of TKM-Ebola was characterized in healthy volunteers in a single escalating 
dose phase I clinical trial [57] with doses ranging from 0.075 to 0.5 mg/kg. The two siRNA, siLpol-2 
and siVP35-2, were shown to have comparable plasma concentration time profiles, suggesting the 
drug PK is mostly ruled by the distribution and metabolism of lipid nanoparticles and this finding can 
be extrapolated to other siRNAs sequences with the same vectorization[35]. Preliminary data obtained 
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from 24 patients suggest a greater than dose-proportional increase in Cmax and an approximately 
dose-proportional increase in the AUC.  
Most of the reported adverse events, fever, rigors, dizziness, chest tightness and raise heart rate can be 
related to transient inflammatory response, started during the first 6 hours of perfusion and 
disappeared within 24 hours post-infusion[16,58]. Furthermore, one severe cytokine release syndrome 
was diagnosed when treated with the highest dose (0.5 mg/kg). Thus, the maximal dose was limited at 
0.3 mg/kg daily for the future studies. 
2.5.2.   Efficacy 
The efficacy of the two components of TKM-Ebola was demonstrated in vitro using both Kikwit and 
Guinea strains on HepG2 cells, with EC50 reported between 50 and 250 ng/mL [55]. A mixture of 
these two siRNA and another targeting VP24 gene (2 mg/kg), was administered to two groups of 
rhesus macaques infected by 1000 pfu of Kikwit EBOV at 30 minutes after infection, followed by 
three doses given at two-day interval (N=3) or six doses given at one-day interval (N=4) for 6 days. 
All monkeys receiving the daily treatment survived compared to two out of three who received two-
day interval treatment[59]. The two most effective siRNA, siLpol-2 and siVP35-2, were selected 
among this cocktail to constitute TKM 100-802 siEbola-2. In a second study, three rhesus monkeys 
infected with EBOV Makona strain (1000 pfu) via intramuscular route were given daily doses of 0.5 
mg/kg of TKM 100-802 siEbola-3 by infusion at day 4 post-infection, when viremia and clinical 
symptoms had well been established [55]. All the three monkeys survived up to day 28 while all the 
two untreated monkeys died on day 8 and 9. Median peak viral load was also strongly reduced (1-4 
log10 copies/mL) in the treatment group compared to the control group [55].  
TKM-Ebola has been used in USA in two adult patients as compassionate treatment in combination 
with extensive supportive care and convalescent plasma [58]. The two patients survived despite of 
severe disease-related clinical and biological alteration. A phase II single arm clinical trial was 
conducted in Sierra Leone to evaluate the efficacy of TKM-Ebola in patients. In July 2015, Tekmira 
announced that a predefined statistical endpoint was reached in an intermediate analysis, indicating the 
trial would be discontinued due to low probability to demonstrate an overall therapeutic benefit [60].  
2.6. AVI-7537 
AVI-7537, developed by Sarepta Therapeutics, is a small RNA-like oligomer, with linkage to a 6-
member ring, instead of the natural 5-member ribose ring of RNA and DNA [61]. This structure, 
called PMOplus, renders the RNA-like oligomer metabolically stable and resistant to DNAse and 
RNAse cleavage. The inclusion of five positive charges in AVI-7537 enhance drug’s stability and its 
binding to the negatively charge RNA [62]. Having the same principle as other antisense therapies, 
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AVI-7537 targets the specific sequences of the VP24 gene of EBOV and interferes with the mRNA 
translation of this protein, therefore, affecting viral replication. Initially in its development, the product 
was part of a compound known as AVI-6002 which contained (in a 1:1 ratio) AVI-7537 and another 
oligomer targeting VP35 (AVI-7539) [62,63]. 
2.6.1.   Pharmacokinetics& Safety 
The pharmacokinetics and safety of AVI-7537 was assessed in a Phase I single-ascending dose study, 
with doses ranging from 0.005 to 4.5 mg/kg [61]. The mean Cmax and AUC values of AVI-7537 
approximatively follow a dose-proportional pharmacokinetics. The half-life was about 2-5 h. Urinary 
excretion of intact drug accounted for no more than 44.0% of the total elimination at the highest dose. 
Other pathways contributing to the elimination of AVI-7537 are uncertain. The AVI-7537 renal 
clearance was not measurable for lower doses (≤0.05 mg/kg) and increased linearly with dose. This is 
likely to be due to low affinity between the PMOplus agent and plasma proteins, resulting in a greater 
filtered fraction in the kidney and the increased steady state volume of distribution observed at higher 
doses, which is about 400 mL/kg, compared to 100-200 ml/kg in low doses (≤0.05 mg/kg). 
AVI-7537 was safe and well tolerated across the doses studied. Adverse effects associated to 
treatment, including gastrointestinal and nervous systems disorders, occurred in 50% of patients 
received AVI-6002, but were dose independent.  
2.6.2.   Efficacy 
AVI-7537 was shown to effectively inhibit viral mRNA translation in a cell-free in vitro translation 
system using rabbit reticulocyte lysate with an EC50 of 585 nM[62]. 
In vivo efficacy of AVI-7537 was evaluated in several NHP studies using rhesus macaques challenged 
with 1000 pfu of EBOV Kikwit strain by intramuscular injection. In two proof-of-concept studies, five 
out of eight rhesus monkeys treated with 40 mg/kg of AVI-6002, starting at 30-60 minutes after the 
challenge survived whereas the untreated monkey died within 7 days [63]. A dose-escalating 
experiment was conducted subsequently, in which rhesus monkeys were treated 30-60 minutes after 
the challenge with either 4 mg/kg (N=5), 16 mg/kg (N=5), 28 mg/kg (N=5) or 40 mg/kg (N=5) of 
AVI-6002 or with a scramble control (PMOplus formulation which does not target the EBOV gene 
sequences) or placebo (N=4 and N=1, respectively) [62,63]. All monkeys in the control and scramble 
control groups died by day 8 after infection. A dose-dependent survival was observed in this study, 
with 0%, 20%, 60% and 60% survival in the groups receiving 4 mg/kg, 16 mg/kg, 28 mg/kg and 40 
mg/kg, respectively[62,63]. In the last study, rhesus monkeys were given intravenously 40 mg/kg of 
either AVI-6002 (N=8), AVI-7537 (N=8), AVI-7539 (N=8) or saline solution (N=6) at 30-60 minutes 
after the challenge then once daily for 14 days [64]. The survival rates were 62.5%, 75%, 0% and 0%, 
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respectively, indicating that AVI-7537 alone was sufficient to confer protection from EBOV infection 
[64]. The peak viral loads following AVI-7537 and AVI-6002 treatments showed no significant 
difference but they were significantly lower than those of AVI-7539 and control groups [64].  
The clinical development of AVI-7527 (AVI-6002) was pending due to funding issues. Based on the 
body surface, the dose of 28-30 mg/kg needed to achieve 50% survival in the NHPs was estimated to 
translate to 9 mg/kg of AVI-6002 or 4.5 mg/kg of AVI-7537 [61]. 
 
2.7. rNAPc2 
The Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), originally cloned from a parasitic 
nematode, Ancylostomacaninum(dog hookworm) [65] is a potent, long-acting anticoagulant developed 
by ARCA Pharma. It was shown to have no intrinsic antiviral action in vitro for a concentration range 
of 0.045–100 µg/mL. This protein, bound to the circulating coagulation Factor X, acts as an inhibitor 
of the complex Factor VIIa/Tissue Factor [65]. This complex physiologically enables the extrinsic 
pathway of the coagulation, and is widely implied in the unregulated disseminated intravascular 
coagulation process leading to hemorrhagic symptoms in patients infected by EBOV [66]. Therefore, 
rNAPc2 was though to limit the coagulopathy and associated complications (renal failure, 
hemorrhage, multiple organ failure) [67].  
2.7.1.   Pharmacokinetics& Safety 
The pharmacokinetics of rNAPc2 was assessed in humans following subcutaneous or intravenous 
administration in three phase I clinical studies using healthy volunteers with the doses ranging from 
0.3 µg/kg to 7.5 µg/kg [67,68]. rNAPc2 was shown to have a linear pharmacokinetics within the 
studied dose range [67,68]. As a result of a high affinity between rNAPc2 and plasma clotting factor 
X, rNAPc2 has a prolonged elimination half-life (t1/2) of more than 50 hours and is distributed 
predominantly in the plasma compartment, leading to a small distribution volume[67,68]. The fact that 
rNAPc2 is closely bound to clotting Factor X in blood circulation, has similar half-life and is not 
detected in the urine suggests that the complex rNAPc2/Factor X may be cleared via the same 
elimination route of the unbound Factor X in the liver[68]. The accumulated data obtained in more 
than 700 patients from several phase I and II clinical studies suggest that rNAPc2 is safe and well 
tolerated following subcutaneous doses up to 10 µg/kg or IV dose up to 7.5 µg/kg in healthy 
volunteers [67–71]. Bleeding was the major side effect [69–71], but was related to invasive procedure 
(surgery and catheterization) or co administration with platelet aggregation inhibitors. This adverse 
effect can be monitored and, if occurs, can be reversed with recombinant Factor VIIa. 
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2.7.2.   Efficacy 
The efficacy of rNAPc2 has been evaluated in a NHP model using rhesus macaques challenged by 
1000 pfu of Zaire 95 Ebola virus [72]. The drug was administered at the dose of 30 µg/kg daily by 
subcutaneous route at 10 minutes (N=6) or 24 hours (N=3) after the viral challenge, respectively. 
Three of the nine treated monkeys survived, whereas all the three monkeys in the control group died. 
The mean survival time of dead animals was significantly longer in treated monkeys (11.7 vs 8.3 
days).  
3. Conclusion 
The 2014-2015 outbreak has accelerated the development of various molecules for the treatment of 
EBOV disease. In this paper, we reviewed available pharmacokinetics/pharmacodynamics information 
of the most advanced therapeutic agents whose effectiveness against EBOV infection has been 
evaluatedin vivo in clinical studies or in animal models.  
The pharmacokinetics information reported in this review was collected only in healthy volunteers. 
However, EBOV disease causes dramatic alteration of vital function [6] in particular renal 
impairment, hepatic necrosis, blood leakage, coagulopathy, multiple organ failure. These systemic 
syndromes, together with therapeutic interventions such as dialysis and large volume electrolyte 
infusions may drastically modify drug plasma concentration [73,74]. Therefore, and in spite of the 
difficulties due to the absence of analytical devices on the field and to the transfer of infectious 
samples to BSL4 facilities, it will remain particularly important to collect frequent measurement of 
drug concentration in infected individuals to fully characterize the drug’s pharmacokinetics in the 
context of EBOV infection.  
For most drugs, NHP model is used to assess the in vivo efficacy before clinical development. 
However, important limitations of this model need to be kept in mind. Firstly, the infection route is 
systematically via intramuscular injection while it is not the common infection route in human [9]. 
Secondly, the inoculum (usually 1000 pfu), set to correspond to the maximal amount of virus 
introduced by a needle stick accident [75], is probably much larger than in most of human infections. 
Partlybecause of these two differences, the evolution of clinical symptoms and death in NHP models is 
much more rapid than in humans. In particular there is no asymptomatic infection cases,no or only 
short incubation period and all untreated animals succumb within 10 days, to compare with an 
incubation period of 2 to 21 days and a mortality rate of 40% to 90%  in humans [3]. As a 
consequence of the short natural history of the NHP infection and of the technical constraints that limit 
the number of experiments, all experiments published relied on early treatment compared to what can 
be done in the clinical setting [6]. In addition, given the small number of animals reported in NHP 
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studies, subtle differences in the experimental conditions, such as the challenge used, the supportive 
care provided to treated animals, the decision process to euthanize animals or the genetic differences 
across NHP species, can be sufficient to substantially modify the outcome of different studies. 
Therefore, the comparison of different NHP experiments should be done with caution, especially when 
they are not yet published in a peer-reviewed journal. 
This review did not pretend to be exhaustive and we made the choice to present only drugs categorized 
in class A and B by WHO. A number of agents that have shown anti-EBOV activity in vitro or in 
vivoin animals were not presented in this review. Among them, we can citebrincidofovir, a broad 
spectrum antiviral developed by Chimerix. Itsdemonstratedin vitro efficacy against EBOV and 
approvalfor other viral infection (CMV) supported itsevaluationin a clinical trial [76]. However, due to 
insufficient enrollment, the study was stopped and the development of brincidofovir for EBOV 
infection was discontinued by Chimerix. Recently, encouraging results of an antiviral developed by 
Gilead, GS-5734, have been reported as late breaker abstract for the annual conference of the 
Infectious Diseases Society of Americaheld in October 2015 [77]. GS-5734 is a prodrug of adenine 
nucleotide analogue, which undergoes fast conversion to a long half-life triphosphate metabolite 
(>10h).GS-5734 inhibits EBOV (Kikwit and Makona strains) with a high in vitroefficacy (EC50 of 
0.01 to 0.2 µM). Intravenous administration with a dose of 10 mg/kg initiated on day 3 led to 100% 
survival and a 5 log10copies/mL reduction of viral load in treated monkeys compared to the placebo 
group [77]. First administration in patient was allowed in October 2015for compassionate care [78]. 
Several new compounds or drugs approved for other indications have also been identified to have 
activity against EBOV in vitro with different mechanisms of action such as preventing viral entry [79–
84] or interfering with viral replication by targeting host factors [85–87]and may warrant future in vivo 
evaluation. Likewise future developments will probably involve combination therapy with drugs 
having different mechanisms of action, as done for other viral infections such as HIV or HCV. For 
instance, the combination of ZMab and IFNα was shown to improve the survival rates in monkeys 
compared to ZMab monotherapy [39] and a drug trial evaluating the combination of favipiravir and 
ZMapp is also planned.  
In severe acute infection, as many patients may already develop high viremia and be in critical 
conditions when treatment starts, it is crucial to rapidly achieve high level of drug exposure. 
Consequently, clinical development plans of these drugs should consider the need for loading doses to 
reach the target exposure as quickly as possible in order to maximize clinical benefits. 
Modeling and simulation of pharmacokinetic data obtained could be of critical importance to support 
the search for an optimal dosing regimen, in particular in sanitary crisis where the need of therapeutic 
response may shorten the usual drug evaluation. Further, and following what has been done in other 
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viral infections, such as influenza or hepatitis C virus[88,89], a better anticipation of the effect of 
drugs on the outcome could be obtained by developing mechanistic model of viremia. However, the 
use of this approach is still limited by the lack of data on the viral kinetics and other markers which 
may be related to treatment outcome. 
Lastly, we focused here on the effect of drugs during acute infection. However some case reports have 
shown the presence of EBOV in semen as well as in ocular aqueous humor three months and nine 
weeks after the clearance of viremia, respectively[90,91]. These findings, if confirmed, suggest that 
antiviral therapy using drugs with high permeability to immune privileged organs may also be needed 
in some patients long after the disappearance of EBOV-related symptoms. 
Overall vaccines remain the best way to prevent and rapidly control future outbreaks [92]. A number 
of vaccine candidates are currently under development, including inactivated virus, virus-like 
particles, DNA vaccines and recombinant viral vector-based vaccines [93]. One of the most advanced 
is rVSV-ZEBOV, a vaccine developed by Merck, showing promising results in an intermediate 
analysis of a phase III trial [94].  
In summary a large number of molecules are currently tested in animals and in clinical trials. These 
drugs, used alone or in combination, hold the promise that significant breakthrough may be done in a 
near future. However for that purpose a lot of information will need to be collected to better 
understand the effect of these drugs on the course of the disease and optimize the search for a cure.  
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Table 1.  
Drug Chemical structure (or source) Molecularweight Target Assay technique References 
Favipiravir  6-fluoro-3-hydroxy-2-pyrazinecarboxamide 
Purine base analogue 
157.1 Viral polymerase High Performance Liquid 
Chromatography (HPLC) with UV 
detection  
[18,20] 
BCX-4430 
 
[(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-
7-yl)-5- 
(hydroxymethyl)pyrrolidine-3,4-diol]  
Adenosine analogue 
 
265.3 Viral polymerase Protein-precipitation and high-
performance liquid chromatography 
using tandem mass spectrometric 
detection (LC-MS/MS) 
 
[27] 
ZMapp  
 
Association of 3 human–mouse chimaeric monoclonal 
antibodies (c13C6, 2G4,c4G7) 
_ Viral glycoprotein ELISA assay [31,32] 
IFNα and β 
 
Protein, single chain of 165/166 amino-acids  17000-27000 Activator of antiviral 
intracellular, innate and 
adaptive immune 
response 
ELISA immunometric assay [42] 
TKM-100802 
 
Two siRNA encapsulated in lipid nanoparticles 
 siEBOV-2: 
siVP35-2: GCAACTCATTGGACATCAT 
siLpol-2: GTACGAAGCTGTATATAAA 
 siEBOV-3:  
siVP35-3: GCAATTCATTGGACATTAT 
siLpol-3: GTACGAAGCTGTACATAAA 
_ L polymerase and viral 
protein 35 mRNAs 
_ [55] 
AVI-7537 
 
RNA-like oligomer with 5 PMOpluslinkages  
Sequence : 5’ GCC +ATG GT+T TT+T TC+T C+AG G 3’ 
6826 Viral protein 24  mRNA Capillary gel electrophoresis and 
fluorescent probe hybridization assay.  
[61] 
rNAPc2 
 
Protein, single chain of 85 amino-acids 9732 Anticoagulant, inhibitor 
of  FVIIa/Tissue factor 
complex 
ELISA immunometric assay [65,68] 
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Table 2. 
Drug Route Time D Cmax AUC tmax t1/2 CL/F Vd/F Reference 
Favipiravir oral First day 400 mg 16.59 mg/mL 39.41 mg.h/L [0.25-0.75] h 1.6 h 10.15L/h 23.4 L Toyama documentation 
 oral First day 1600 mg 59.43 mg/mL 397.79 mg.h/L [0.5-1.5] h 4.6 h 4.02 L/h 26.7 L Toyama documentation 
 oral First day 2400 mg 92.17 mg/mL 1297.56 mg.h/L [0.75-3] h 4.5 h 1.85 L/h 12.0 L Toyama documentation 
 oral Steady state 400 mg BID 30.56 mg/L 193.69 mg.h/mL [0.5-2] h 4.5 h 2.07 L/h 13.4 L Toyama documentation 
 oral Steady state 600 mg BID 61.50 mg/L 470.53 mg.h/mL [0.5-1.5] h 5.8 h 1.28 L/h 10.7 L Toyama documentation 
IFNα IV 
 
First day 36 MIU _ _ _ [3.7-8.5] 
h 
[0.13-0.22] 
L/h/kg 
[0.22-0.75] 
L/kg 
[49] 
 IV First day 5 MIU 188.2 IU/mL 208 IU.h/mL 0.5 h 1.7 h 24.04 L/h 23.6 L [48] 
 IM First day 5 MIU 47.6 IU/mL 518.7 IU.h/mL 6.7 h 2.2 h 9.64 L/h 30.6 L [48] 
IFNβ IV/IM/ 
subcutaneous 
First day [5-10] 
MIU/m2 
_ _ [3-12] h [2-7] h _ _ [49] 
 IM First day 12 MIU 25.9 IU/mL 657 IU.h/mL 12.6 h _ 18.26 L/h _ [50] 
 IM Steady state 12 MIU every 
two weeks 
23.9 IU/mL 634 IU.h/mL 15.3 h _ 18.93 L/h _ [50] 
AVI-7537 IV First day 1.5 mg/kg 6460 ng/mL 10100 ng.h/mL 0.5 h 2.8 h 152 mL/h/kg 406 mL/kg [61] 
 IV First day 3.0 mg/kg 20900 ng/mL 27000 ng.h/mL 0.5 h 4.6 h 114 mL/h/kg 334 mL/kg [61] 
 IV First day 4.5  mg/kg 24100 ng/mL 35300 ng.h/mL 0.5 h 4.0 h 126 mL/h/kg 453 mL/kg [61] 
rNAPc2 subcutaneous First day 0.7 µg/kg 17.2 ng/mL 505 ng.h/mL 7 h 52.0 h 0.7 mL/h/kg 48 mL/kg [68] 
 subcutaneous First day 3.5 µg/kg 80.3 ng/mL 2471 ng.h/mL 7 h 44.2 h 0.8 mL/h/kg 46 mL/kg [68] 
 subcutaneous First day 5 µg/kg 108.8 ng/mL 3379 ng.h/mL 9 h 49.6 h 0.7 mL/h/kg 51 mL/kg [68] 
 subcutaneous Steady state 1.5 µg/kg 
every 2 days 
66.8 ng/mL 2441 ng.h/mL 8 h 78.9 h 0.622 mL/h/kg 70.9 mL/kg [68] 
 subcutaneous Steady state 3 µg/kg 
every 2 days 
116 ng/mL 4351 ng.h/mL 7 h 70.8 h 0.702 mL/h/kg 72.8 mL/kg [68] 
 subcutaneous Steady state 5 µg/kg 
every 2 days 
213 ng/mL 8491 ng.h/mL 12 h 71.9 h 0.591 mL/h/kg 61.5 mL/kg [68] 
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Table 3. 
Drug EC50 Viral strain Cells Measurement method Reference 
Favipiravir 
(T705) 
10 μg/mL Mayinga 1976 Vero E6 reduction of viral titer (immuno-assay) [21] 
  31-63 μg/mL Kikwit 1995/E718 Vero E6 percentage EBOV plaque reduction (cytopathiceffect) [22] 
BCX-4430 11.8 μmol/L Kikwit 1995 HeLa inhibition of viral replication [27] 
ZMapp 1 µg/mL (13C6) Gueckedou 2014 Vero E6 percentage EBOV plaque reduction (cytopathic effect) [31] 
  < 0.1 µg/mL (2G4) Gueckedou 2014 Vero E6 percentage EBOV plaque reduction (cytopathic effect) [31] 
  0.1  µg/mL (4G7) Gueckedou 2014 Vero E6 percentage EBOV plaque reduction (cytopathic effect) [31] 
albumin-INFα 23.3 pmol/L Engineered EBOV 
expressing GFP 
Vero E6 reduction of viral titer (fluorescence measurement) [51] 
albumin-INFβ < 4.7 pmol/L Engineered EBOV 
expressing GFP 
Vero E6 reduction of viral titer (fluorescence measurement) [51] 
TKM-
100802siEbol
a3 
50 ng/mL 
50-100 ng/mL 
Makona 2014 
Kikwit 1995 
HepG2 inhibition of viral mRNA production by high-content imaging 
assays 
[55] 
TKM-100802 
siEbola2 
100-250 ng/mL 
1-50 ng/mL 
Makona 2014 
Kikwit 1995 
HepG2 inhibition of viral mRNA production by high-content imaging 
assays 
[55] 
AVI-7537 585 nmol/L _ _  Inhibition of viral mRNA translation [62] 
rNAPc2 > 100 µg/mL Kikwit 1995 Vero E6 percentage EBOV plaque reduction (cytopathic effect) [72] 
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Table 4. 
Drug 
Macaque 
species 
Number of 
monkeys/ 
group 
Ebola strain Dosing and route 
Treatment 
initiation related 
to viral challenge 
Overall survival in 
experimental group 
Median survival in 
experimental group 
(days) 
Median survival in 
control group (days) 
Reference 
favipiravir _ _ _ _ _ _ _ _ _ 
BCX-4430 Rhesus 6 _ 16 mg/kg BID IM 0.5 to 4 h 66.7% _ 8 [29] 
 
Rhesus 6 _ 25 mg/kg BID IM 0.5 to 4 h 100.0% _ 8 [29] 
 
Cynomolgus 6 _ 16 mg/kg BID IM 2 days 0.0% 12 7 [28] 
ZMapp Rhesus 18 Kikwit 1995 
50 mg/kg, 3 doses with 
3 days interval IV 
3, 4, 5 days 100.0% > 25 8 [31] 
INFα Cynomolgus 4 Kikwit 1995 20 MU/kg daily IM 18 h 0.0% 7.5 6 [52] 
INFβ Rhesus 5 Kikwit 1995 
10.5 µg/kg every two 
days subcutaneous 
injections 
1 and 18 h 0.0% 10 8 [53] 
 
Rhesus 5 Kikwit 1995 
35 µg/kg daily 
subcutaneous injections 
1 h 0.0% 9 8 [53] 
TKM-
100802 
siEbola-2 
Rhesus 6 Kikwit 1995 0.2 mg/kg once daily IV 1.5 h 66.0% _ _ [35] 
 
Rhesus 6 Kikwit 1995 0.5 mg/kg once daily IV 1.5 h 100.0% _ _ [35] 
 
Rhesus 6 Kikwit 1995 0.5 mg/kg once daily IV 1 days 83.3% _ _ [35] 
 
Rhesus 6 Kikwit 1995 0.5 mg/kg once daily IV 2 days 50.0% _ _ [35] 
 
Rhesus 6 Kikwit 1995 0.5 mg/kg once daily IV 3 days 66.7% _ _ [35] 
 
Rhesus 6 Kikwit 1995 0.5 mg/kg once daily IV 4 days 0.0% _ _ [35] 
TKM-
100802 
siEbola-3 
Rhesus 3 Makona 2014 0.5 mg/kg once daily IV 3 dpi 100.0% > 25 9 [55] 
AVI-7537 Rhesus 13 Kikwit 1995 
20 mg/kg once daily IV 
(in combination with 
AVI-7539 at 1:1 ratio) 
1 h 61.5% > 25 7 [63] 
 
Rhesus 8 Kikwit 1995 
20 mg/kg once daily IV 
(in combination with 
1 h 62.5% > 25 8 [64] 
5 
 
AVI-7539 at 1:1 ratio) 
 
Rhesus 8 Kikwit 1995 40 mg/kg once daily IV 1 h 75.0% > 25 8 [64] 
rNAPc2 Rhesus 9 Kikwit 1995 
30 µg/kg daily 
subcutaneous injections 
10 min or 24 h 33.3% 14 8 [72] 
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Tables and Figures captions: 
Table 1. Chemical structure, molecular weight, target and assay technique of the Ebola drugs 
candidates 
Table 2. Pharmacokinetic parameters of Ebola drugs candidates obtained in healthy volunteers and 
calculated by non-compartmental analysis. Data were not available for BCX4430, ZMapp and TKM-
Ebola. Ranges represent minimum and maximal reported value of the parameter. 
Table 3. In vitro experiment conditions and efficacy (EC50) of the Ebola drug candidates 
Table 4. Summary of survival rates obtained in nonhuman primate experiments with different Ebola 
drug candidates. Viral challenge was performed injecting 1000 pfu of the mentioned viral strain by 
intramuscular route, excepted for ZMapp study, where inoculum was 628 pfu and BCX4430 studies, 
where this data is not available. Survival rate in control group was 0% for the different reported 
studies, excepted for study [72], where 1 of 17 NHP survived. 
 
Figure 1. Structure of Ebola virus. EBOV is an enveloped virus presenting a single-stranded RNA 
genome of nearly 19000 nucleotides, encoding seven proteins: structural nucleoprotein (NP), 
polymerase cofactor (VP 35), VP 40, transcription activator (VP30), VP24, RNA-dependent RNA 
polymerase (L) and Glycoprotein (GP). GP, also expressed in a soluble form (sGP), is responsible for 
host receptor binding and fusion with the cell membrane. Reproduced from Choi and Croyle. Biodrugs 
2013[7]. 
Figure 2. Ebola viral lifecycle and targets of different therapeutic classes. Steps of virus life cycle: (1) 
attachment, (2) fusion with endosomal membranes, (3) nucleocapsid release, (4) mRNA transcription, 
(5) viral protein translation, (6) genome replication and (7) viral assembly and release. Polymerase 
inhibitors hamper replication and transcription processes (4)(6), directly targeting the viral polymerase 
L. Monoclonal antibodies (ZMapp, MIL-77) binds to viral glycoprotein and therefore inhibit viral 
attachment (1) but also increase virions and infected cells clearance (not represented). Interfering 
RNAs inhibit the viral mRNA translation process (5), and enhance viral mRNA degradation. Type I 
interferons have pleiotropic indirect effects through host cell genes regulation, leading to viral mRNA 
degradation, inhibition of viral transcription (4) and translation (5), interference with the release of 
viral particles(7), facilitation apoptosis of infected cells and enhancement of innate and adaptive 
immune response (not represented). Modified from Yazdanpanah et al, Intensive Care Medicine 2015 
[13]. 
Figure 3. Survival of NHP infected by EBOV and treated with highest doses of candidates drugs. Data 
from rhesus macaques and cynomolgus macaques are in red and blue, respectively. Colored solid line 
stands for post exposure prophylaxis experiments (treatment initiation within 24h post challenge), 
colored dashed line for curative treatment (treatment initiation after 24h post challenge and black line 
for untreated control) + marks the end of study following. Survival plots were drawn from data 
reported in [28,29,31,52,53,55,64,72]using the dose where the best survival rate was observed. 
